ORGANIC
LETTERS
2001
Vol. 3, No. 19
2949-2951
Enantioselective Synthesis of the
Oxadecalin Core of Phomactin A via a
Highly Stereoselective Diels−Alder
Reaction
Sherry R. Chemler, Ulrich Iserloh, and Samuel J. Danishefsky*
Laboratory of Bioorganic Chemistry, Sloan-Kettering Institute for Cancer Research,
1275 York AVenue, Box 106, New York, New York 10021, and Department of
Chemistry, Columbia UniVersity, HaVemeyer Hall, New York, New York 10027
Received May 17, 2001
ABSTRACT
Phomactin A (1) is a selective antagonist of platelet activating factor (PAF). Herein, we report our progress toward the construction of the
oxadecalin core of 1. This route is based on the Diels−Alder cycloaddition of an appropriately functionalized vinyl pyran and a complementary
dienophile. A model of this reaction involving 2 and maleic anhydride was conducted. Adduct 3 contains the correct stereochemical arrangements
between functional groups necessary for gaining access to phomactin A.
Phomactin A (1), isolated from the marine fungus Phoma
sp. by Sugano and co-workers in 1991, is a selective
antagonist of platelet activating factor (PAF), 1-O-alkyl-2(R)-
(acetylglyceryl)-3-phosphorylcholine.1 Agent 1 is one of the
most structurally complex members of a class of related
compounds, phomactins A-G.2 PAF-mediated signaling has
been implicated in a variety of biological effects that include
platelet aggregation, hypotension, smooth muscle contraction,
and vascular permeability.3 PAF is also implicated as a
causative factor in septic shock and inflammatory, respira-
tory, and cardiovascular diseases.4
Aside from the biology-driven incentives, a total synthesis
exercise directed at phomactin A offers an attractive testing
ground for exploring and evaluating strategy level initiatives.
Indeed, several groups have reported approaches toward the
synthesis of phomactin A (for the moment in racemic form).
However, a solution to the problem has not yet been
described.5 Approaches toward phomactin D have also been
described, and an enantioselective total synthesis of this
molecule has been achieved.6
Phomactin A contains six stereogenic centers in its
oxadecalin core. An additional ansa-like bridge connects the
(4) (a) Heuer, H. Lipids 1991, 26, 1369-1373. (b) Bazen, N. G.; Squinto,
S. P.; Branquet, P.; Panetta, T.; Marchelselli, V. L. Lipids 1991, 26, 1236-
1242. (c) Uchiyama, S.; Yamazaki, M.; Maruyama, S. Lipids 1991, 26,
1280-1282. (d) Chung, K. F.; Barnes, P. J. Lipids 1991, 26, 1277-1279.
(e) Page, C. P. Lipids 1991, 26, 1280-1282. (f) Godfroid, J. J.; Dive, G.;
Lamotte-Brasseur, J.; Batt, J. P.; Heymans, F. Lipids 1991, 26, 1162-1166.
(g) Lamotte-Brasseur, J.; Heymans, F.; Dive, G.; Lamouri, A.; Batt, J. P.;
Redeuilh, C. Lipids 1991, 26, 1167-1171.
(5) (a) Foote, K. M.; Hayes, C. J.; Pattenden, G. Tetrahedron Lett. 1996,
37, 275-278. (b) Seth, P. P.; Totah, N. I. Org. Lett. 2000, 2, 2507-2509.
(c) Mi, B.; Maleczka, R. E., Jr. Org. Lett. 2001, 3, 1491-1494. (d) Foote,
K. M.; John, M.; Pattenden, G. Synlett 2001, 3, 365-368.
(1) Sugano, M.; Sato, A.; Iijima, Y.; Oshima, T.; Furuya, K.; Kuwano,
H.; Hata, T.; Hanzawa, H. J. Am. Chem. Soc. 1991, 113, 5463-5464.
(2) (a) Sugano, M.; Sato, A.; Iijima, Y.; Furuya, K.; Haruyama, H.; Yoda,
K.; Hata, T. J. Org. Chem. 1994, 59, 564-569. (b) Sugano, M.; Sato, A.;
Iijima, Y.; Furuya, K.; Kuwano, H.; Hata, T. J. Antibiot. 1995, 48, 1188.
(c) Chu, M.; Patel, M. G.; Gullo, V. P.; Truumees, I.; Puar, M. S.; McPhail,
A. T. J. Org. Chem. 1992, 57, 5817-5818.
(3) (a) Koltai, M.; Braquet, P. G. Clin. ReV. Allergy 1994, 12, 361-
380. (b) Goldstein, R. E.; Feuerstein, G. Z.; Bradley, L. M.; Stambouly, J.
J.; Laurindo, F. R. M.; Davenport, N. J. Lipids 1991, 26, 1250-1256. (c)
Rabinovici, R.; Yue, T.-L.; Feuerstein, G. Lipids 1991, 26, 1369-1373.
10.1021/ol0161357 CCC: $20.00 © 2001 American Chemical Society
Published on Web 08/23/2001